Vimarsana
Biggest News Aggregation in the World

Geoff Obrien News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Geoff Obrien. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Geoff Obrien Today - Breaking & Trending Today

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) - MediciNova (NASDAQ:MNOV) - Vimarsana News

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) - MediciNova (NASDAQ:MNOV)

Published: April 3, 2024

LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number:

Source: benzinga.com
Related Topics:
United StatesGeoff ObrienGilbert YoussefOncology At Dana Farber Cancer InstituteAmerican Society Of Clinical OncologyExchange CommissionPhysician At Harvard Medical SchoolMedicinova IncStandard MarketTokyo Stock ExchangeCode NumberAmerican SocietyClinical OncologyAnnual MeetingAttending PhysicianHarvard Medical SchoolDana Farber Cancer InstituteRapid Oral AbstractCentral Nervous SystemPrivate Securities Litigation Reform Act
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) - Vimarsana News

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

Published: April 2, 2024

LA JOLLA, Calif., April 02, 2024 -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the Standard Market of the Tokyo Stock Exchange , today announced that an...

Source: marketscreener.com
Related Topics:
United StatesGilbert YoussefGeoff ObrienExchange CommissionPhysician At Harvard Medical SchoolMedicinova IncOncology At Dana Farber Cancer InstituteAmerican Society Of Clinical OncologyStandard MarketTokyo Stock ExchangeCode NumberAmerican SocietyClinical OncologyAnnual MeetingAttending PhysicianHarvard Medical SchoolDana Farber Cancer InstituteRapid Oral AbstractCentral Nervous SystemPrivate Securities Litigation Reform Act
MediciNova Announces Abstract Regarding Results of a - Vimarsana News

MediciNova Announces Abstract Regarding Results of a

Published: April 2, 2024

LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and...

Source: globenewswire.com
Related Topics:
United StatesGilbert YoussefGeoff ObrienOncology At Dana Farber Cancer InstituteExchange CommissionAmerican Society Of Clinical OncologyPhysician At Harvard Medical SchoolMedicinova IncStandard MarketTokyo Stock ExchangeCode NumberAmerican SocietyClinical OncologyAnnual MeetingAttending PhysicianHarvard Medical SchoolDana Farber Cancer InstituteRapid Oral AbstractCentral Nervous SystemPrivate Securities Litigation Reform ActNasdaq Mnov
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology - Vimarsana News

MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology

Published: March 12, 2024

LA JOLLA, Calif., March 12, 2024 -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the Standard Market of the Tokyo Stock Exchange , today announced that...

Source: marketscreener.com
Related Topics:
United StatesPerenlei EnkhbaatarGeoff ObrienCharles Robert AllenMedicinova IncUniversity Of Texas Medical BranchSociety Of ToxicologyDepartment Of AnesthesiologyExchange CommissionStandard MarketTokyo Stock ExchangeCode NumberTranslational Intensive Care UnitCharles Robert Allen ProfessorTexas Medical BranchAnnual MeetingSalt Lake CityPrivate Securities Litigation Reform Act
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China - MediciNova (NASDAQ:MNOV) - Vimarsana News

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China - MediciNova (NASDAQ:MNOV)

Published: January 17, 2024

LA JOLLA, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number:

Source: benzinga.com
Related Topics:
Geoff ObrienKazuko MatsudaExchange CommissionChinese Patent OfficeMedicinova IncStandard MarketTokyo Stock ExchangeCode NumberChief Medical OfficerOptical Coherence TomographyPrivate Securities Litigation Reform Act